Cargando…
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
Therapeutic implications of intra-tumor heterogeneity are still undefined. In this study we report a genetic and functional analysis aimed at defining the mechanisms of chemoresistance in a 43-year old woman affected by stage IVB Burkitt lymphoma with bulky abdominal masses and peritoneal effusion....
Autores principales: | Derenzini, Enrico, Iacobucci, Ilaria, Agostinelli, Claudio, Imbrogno, Enrica, Storlazzi, Clelia Tiziana, L`Abbate, Alberto, Casadei, Beatrice, Ferrari, Anna, Di Rora`, Andrea Ghelli Luserna, Martinelli, Giovanni, Pileri, Stefano, Zinzani, Pier Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549912/ https://www.ncbi.nlm.nih.gov/pubmed/26312160 http://dx.doi.org/10.1186/s40164-015-0019-9 |
Ejemplares similares
-
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015) -
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016) -
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2015) -
The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017) -
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)